Industry Leaders
-
Should Your Executives Help You Recruit?
1/1/2016
No industry is more competitive than the life sciences for leadership talent. And we all know there are obvious advantages to asking one’s own leaders to help recruit, but allow me to offer a few words of caution if this is your strategy.
-
How Much Transparency Is Too Much With Clinical Trials?
11/1/2015
There is a growing movement by some researchers and regulators to increase disclosure of clinical trial results.
-
A Life Science Manufacturing Executive’s Role In Establishing A Quality Culture
11/1/2015
Creating the appropriate quality culture is arguably the most important element of being a manufacturing leader in the life sciences industry. Yet, reflecting back on my long career, I have not seen a single recipe for doing this, and I don’t profess to have a well-documented approach myself. But, boy, do I have some stories.
-
The Challenges Surrounding Immunology
10/1/2015
Immunotherapy is a growing trend within the oncology industry, as the traditional processes, methods, and equipment used in the fight against cancer are evolving and adapting constantly in order to try to find the most effective cure. Traditional treatments like chemotherapy and radiation remain effective methods of fighting the disease; however, recent research has started to shift away from aggressive indiscriminate treatments toward more targeted therapies.
-
Does Pharma Demand Forecasting Keep You Awake At Night?
10/1/2015
Given the uniquely long and winding road pharmaceuticals must take to market, it is difficult for developers to predict the manufacturing capacity they will need when their product finally gets there.
-
Quality In The Biologics Discovery And Development Continuum
9/1/2015
With biologics filling the pipelines of life sciences companies more than ever, the industry needs to rethink its view toward quality. Once primarily considered a focus in downstream drug development and manufacturing, the issue of quality now demands attention in upstream discovery research as well. In fact, the line between discovery and development in biologics looks more like the intersection of a Venn diagram than a line at all, with discovery and development sharing space in the drug development quality continuum.
-
How Serialization Can Help Your Pharma Brand
9/1/2015
By now you probably know that serialization is your best option for combatting counterfeit pharmaceuticals. Unfortunately, you probably also understand that developing and implementing a serialization plan is no simple task. Your packaging, warehousing, and supply chain processes all will be altered, which involves a lot of change management for any organization. The primary goal, of course, is safe and secure drugs for patients, and yes, regulatory compliance is part of the equation. But many people underestimate the additional positive effect serialization can have on a company’s brand.
-
Integrating The Digital And Physical Supply Chain In Clinical Trials
5/26/2015
For decades, the pharmaceutical industry was characterized as risk averse, conservative, and slow to change. In such an environment, being a change agent was not often a job requirement. That’s no longer the case, as innovation outside the laboratory is valued as never before. One change ready to be explored is improving the efficiency and effectiveness of the clinical supply chain by adopting a holistic model that will minimize costs, increase agility and control, and provide greater traceability.
-
What Big Pharma Can Do To Combat The Latest Patent Cliff
3/31/2015
The patent cliff era is far from over for the pharma industry. In the last three years, some of the biggest drugmakers have seen their blockbuster patents expire, a trend that will only increase going forward. A recent study by GlobalData estimates the industry will lose more than $60 billion in revenue through the end of 2019 due to the patent cliff.
-
6 Questions To Answer Before Considering A Carve-Out
2/25/2015
Carve-out transactions are no walk in the park. Forming an entirely new entity is extremely difficult, especially when you consider the many moving parts that have to be managed all at one time.